分析师观点:
特发性肺纤维化是一种影响肺部肺泡周围组织的慢性疾病。当肺组织因不明原因变得僵硬变厚时,就会出现这种情况,随着时间的推移,这些变化会导致肺部永久性疤痕,从而导致患者呼吸困难。目前,特发性肺纤维化尚无精确治愈方法。肺康复、药物和外科手术等治疗可减缓肺部损伤,有助于提高患者的生活质量。
特发性肺纤维化患病率不断上升,吸烟人数不断增加,推动了对有效治疗药物的需求未来几年。正在进行的研究工作旨在推出治疗特发性肺纤维化的有效药物,未来可能会进一步使市场受益。目前,发达市场和新兴市场的医疗保健支出都在增加,预计这将鼓励该市场的制造商集中精力开发新的创新产品。
市场概述:
纤维化是结缔组织的沉积作为正常愈合过程的一部分发生的组织或作为病理过程发生的多余组织的沉积。特发性肺纤维化影响肺部和肺泡(肺部的气囊)中的结缔组织。这种情况可能会导致人们在执行日常任务时呼吸急促,这对于健康状况良好的人来说并不令人厌倦。特发性肺纤维化治疗市场的增长归因于纤维化疾病负担的增加和吸烟人数的激增。快节奏的研发活动带来了治疗技术的进步,预计将在未来几年为特发性肺纤维化治疗市场提供增长机会。
市场驱动因素:
日益增长的负担特发性肺纤维化推动特发性肺纤维化治疗市场
根据美国肺脏协会 2022 年 11 月更新的数据,美国每年诊断出约 50,000 例新发特发性肺纤维化病例。这种情况的症状在 50-70 岁的患者中更为明显。根据 2022 年 9 月发表在《英国医学杂志》上的一篇文章,预计 2021 年专科护理病房中特发性肺纤维化的患病率为每 10 万人中 36.0 人。由于老龄化、肥胖、高血压或家族史等常见危险因素,全世界患有特发性肺纤维化的患者数量不断增加,并且该病正在成为经济体的重大社会经济负担。因此,特发性肺纤维化患者数量的增加推动了纤维化疾病治疗市场的增长。
细分分析:
根据药物类型,特发性肺纤维化治疗市场分为尼达尼布、吡非尼酮等。尼达尼布细分市场在 2022 年占据了更大的市场份额。预计其他细分市场在 2022 年至 2030 年期间的复合年增长率将达到 46.3%。吡非尼酮和尼达尼布是治疗纤维化疾病的常用药物。
区域分析:
北美主导全球特发性肺纤维化治疗市场。 2022年北美市场价值为23.6295亿美元,预计到2030年将达到55.2728亿美元;预计 2022 年至 2030 年复合年增长率为 11.2%。北美特发性肺纤维化治疗市场分为美国、加拿大和墨西哥。特发性肺纤维化负担的增加和治疗技术的进步有利于北美特发性肺纤维化治疗市场。主要市场参与者的产品推出和战略举措也有助于市场增长。随着治疗特发性肺纤维化的研发活动不断增多,改进的药物不断被引入市场,从而使更多的患者能够更好地获得药物。此外,FDA 在该地区的广泛批准鼓励公司推出技术先进的产品。
随着特发性肺纤维化患病率的上升和医疗保健支出的高昂,欧洲在全球纤维化疾病治疗市场中占据第二大份额。由于能够更好地获得医疗保健领域技术先进的产品和服务,德国预计将主导欧洲特发性肺纤维化治疗市场。
预计亚太地区将在 2022 年实现全球特发性肺纤维化治疗市场最快的复合年增长率 – 2030年。预计的市场增长可归功于尖端技术的广泛接受和采用,这些技术可以在更短的时间内产生准确的结果。该地区的医疗保健行业正在利用人工智能、自动化和数字化转型的创新,提高效率和生产力医疗专业人员。各行业的持续转型增强了亚太地区的企业和经济,使它们能够将自己定位为发展最快的中心,并以动态和前瞻性的方式实现可持续发展。
主要参与者分析:
特发性肺纤维化治疗市场分析基于基因泰克公司和勃林格殷格翰国际有限公司等主要参与者。
最新动态:
特发性肺纤维化治疗市场的公司高度采用并购等无机和有机策略。以下列出了一些最新进展:
2023 年 5 月,勃林格殷格翰启动了突破性 IL-11 抑制剂抗体 BI 765423 的临床开发。第一阶段研究 (NCT05658107) 重点评估其在健康志愿者受试者中的安全性、耐受性和药代动力学。临床前研究表明,这种抗 IL-11 药物在抑制和潜在逆转各种纤维化病例中的纤维化方面具有良好的结果。 2022 年 10 月,勃林格殷格翰在评估 BI 1015550 的 FIBRONEER-IPF III 期研究中招募了第一位美国患者。 BI 1015550是一种实验性磷酸二酯酶 4B (PDE4B) 抑制剂,被发现用于治疗患有特发性肺纤维化的个体。该研究是全球 FIBRONEER 计划的一部分,该计划包括两项 III 期研究:针对特发性肺纤维化患者的 FIBRONEER-IPF 和针对患有其他进行性纤维化间质性肺疾病 (ILD) 的成人患者的 FIBRONEER-ILD。 2022 年 9 月,Bellerophon Therapeutics , Inc. 宣布 FDA 接受了 INOpulse 目前 REBUILD 3 期注册试验的试验规模缩减申请,该试验适用于治疗纤维化间质性肺疾病 (LD)。 2022年5月,全球药品安全解决方案领导者ArisGlobal收购了勃林格殷格翰的BRASS数字创新产品。此次收购使前者能够通过将 BRASS 集成到 LifeSphere Clarity 中来增强其 LifeSphere 技术平台。这种整合促进了整个行业药物警戒和患者安全的进步。此外,ArisGlobal还在全球多个地区拓展了临床诊断业务布局,巩固了其全球地位。 2022年3月,领先制药公司百时美施贵宝宣布通过ArisGlobal以每股76.00美元收购Turning Point Therapeutics, Inc.最终合并协议。此次收购显着增强了百时美施贵宝在制药市场的全球影响力,使其能够更加积极主动地为行业带来创新,同时扩大其挽救生命的疗法和治疗组合。
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The global fibrotic diseases treatment market, based on treatment, is segmented into drug type and distribution channel. Based on drug type, the idiopathic pulmonary fibrosis treatment market is segmented into nintedanib, pirfenidone, and others. The nintedanib segment held a larger market share in 2022. The others segment is anticipated to register a higher CAGR of 46.3% during 2022–2030. Pirfenidone and nintedanib are the popular medicines prescribed to treat fibrotic diseases.
By distribution channel, the global idiopathic pulmonary fibrosis treatment market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest market share in 2022. The online pharmacies segment is anticipated to register the highest CAGR of 17.4% during 2022–2030.
The enteral nutrition market is expected to be valued at US$ 10,784.07 million in 2030.
The fibrotic diseases treatment market was valued at US$ 4,360.87 million in 2022.
The fibrotic diseases treatment market majorly consists of the players such as F. Hoffmann-La Roche Ltd; C.H. Boehringer Ingelheim International GmbH; AstraZeneca.; Bristol-Myers Squibb Company; Shionogi and Co. Ltd.; and Cipla Ltd.
Idiopathic pulmonary fibrosis is a chronic condition that affects the tissue surrounding the alveoli in the lungs. It develops when lung tissues become stiff and thick for unknown reasons, and these changes result in permanent scarring in the lungs over time, which makes breathing difficult among patients. Currently, there is no precise cure for idiopathic pulmonary fibrosis. Treatments such as pulmonary rehabilitation, medicines, and surgical procedures slow down lung damage and help enhance the quality of patients’ lives.
The growth of the idiopathic pulmonary fibrosis treatment market is attributed to the surging burden of idiopathic pulmonary fibrosis and the increasing number of people smoking cigarettes.
Trends and growth analysis reports related to Life Sciences : READ MORE..
The List of Companies - Fibrotic Diseases Treatment Market
- C.H. Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- AstraZeneca
- Shionogi and Co. Ltd.
- Cipla Ltd
- Others
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.